All Stories

  1. Mitotic quiescence, but not unique “stemness,” marks the phenotype of bone metastasis-initiating cells in prostate cancer

    Article • The FASEB Journal, August 2015, Federation of American Societies For Experimental Biology (FASEB)

    Dr Penelope Dawn Ottewell

  2. Molecular alterations that drive breast cancer metastasis to bone

    Article • BoneKEy Reports, March 2015, Portico

    Dr Penelope Dawn Ottewell

  3. The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway

    Article • BMC Cancer, February 2015, Springer Science + Business Media

    Dr Penelope Dawn Ottewell

  4. OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone

    Article • International Journal of Cancer, February 2015, Wiley

    Dr Penelope Dawn Ottewell

  5. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone

    Article • July 2014, Bioscientifica

    Dr Penelope Dawn Ottewell

  6. Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo

    Article • Clinical Cancer Research, March 2014, American Association for Cancer Research (AACR)

    Dr Penelope Dawn Ottewell

  7. Lysophosphatidic Acid Receptor Type 1 (LPA 1 ) Plays a Functional Role in Osteoclast Differentiation and Bone Resorption Activity

    Article • Journal of Biological Chemistry, January 2014, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Penelope Dawn Ottewell

  8. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line

    Article • January 2014, Bioscientifica

    Dr Penelope Dawn Ottewell

  9. Macrophages as potential targets for zoledronic acid outside the skeleton—evidence from in vitro and in vivo models

    Article • Cellular Oncology, November 2013, Springer Science + Business Media

    Dr Penelope Dawn Ottewell

  10. Abstract PD07-08: Zoledronic acid specifically inhibits development of bone metastases in the post-menopausal setting – evidence from an in vivo breast cancer model

    Article • Cancer Research, December 2012, American Association for Cancer Research (AACR)

    Dr Penelope Dawn Ottewell

  11. A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts

    Article • Journal of Bone Oncology, September 2012, Elsevier

    Dr Penelope Dawn Ottewell

  12. Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo

    Article • May 2012, Springer Science + Business Media

    Dr Penelope Dawn Ottewell

  13. Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo

    Article • Clinical & Experimental Metastasis, May 2012, Springer Science + Business Media

    Dr Penelope Dawn Ottewell

  14. 11th International Conference on Cancer-Induced Bone Disease

    Article • IBMS BoneKEy, March 2012, Portico

    Dr Penelope Dawn Ottewell

  15. P2-01-20: Reduced Plakoglobin Expression Increases the Metastatic Potential of Breast Cancer Cells.

    Article • Cancer Research, December 2011, American Association for Cancer Research (AACR)

    Dr Penelope Dawn Ottewell

  16. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice

    Article • Breast Cancer Research and Treatment, September 2011, Springer Science + Business Media

    Dr Penelope Dawn Ottewell

  17. Early intervention with a single dose of doxorubicin followed by zoledronic acid induces sustained inhibition of breast cancer-induced bone disease in a mouse model

    Article • Bone, May 2011, Elsevier

    Dr Penelope Dawn Ottewell

  18. Meeting report from the 10th international conference on cancer-induced bone disease

    Article • IBMS BoneKEy, January 2011, Portico

    Dr Penelope Dawn Ottewell

  19. Towards biomarkers of bone-metastasis using cellular proteomics

    Article • Bone, January 2011, Elsevier

    Dr Penelope Dawn Ottewell

  20. Changes in osteoblast and osteoclast number rely on direct contact with breast cancer cells — Evidence from a longitudinal study of bone metastasis

    Article • Bone, January 2011, Elsevier

    Dr Penelope Dawn Ottewell

  21. First evidence for anti-tumour effects of doxorubicin and zoledronic acid from an immunocompetent mouse model

    Article • Bone, January 2011, Elsevier

    Dr Penelope Dawn Ottewell

  22. Does differential expression of CD151 affect the ability of beast cancer cells to establish tumours in bone?

    Article • Bone, January 2011, Elsevier

    Dr Penelope Dawn Ottewell

  23. Combination vs single agent treatment: The effects of zoledronic acid+/−doxorubicin on breast tumour growth in bone prior to development of osteolytic bone disease

    Article • Bone, January 2011, Elsevier

    Dr Penelope Dawn Ottewell

  24. Abstract P6-14-03: Zoledronic Acid Reduces Breast Tumour Growth When Combined with Chemotherapy — Emerging Evidence of Anti-Tumour Effects Outside Bone

    Article • Cancer Research, December 2010, American Association for Cancer Research (AACR)

    Dr Penelope Dawn Ottewell

  25. Combined Therapies of Bone Disease with Bisphosphonates

    Article • Current Pharmaceutical Design, September 2010, Bentham Science Publishers

    Dr Penelope Dawn Ottewell

  26. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model

    Article • International Journal of Cancer, January 2010, Wiley

    Dr Penelope Dawn Ottewell

  27. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells

    Article • Journal of Cellular and Molecular Medicine, December 2009, Wiley

    Dr Penelope Dawn Ottewell

  28. Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.

    Article • Cancer Research, January 2009, American Association for Cancer Research (AACR)

    Dr Penelope Dawn Ottewell

  29. Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer

    Article • JNCI Journal of the National Cancer Institute, August 2008, Oxford University Press (OUP)

    Dr Penelope Dawn Ottewell

  30. Differential Effect of Doxorubicin and Zoledronic Acid on Intraosseous versus Extraosseous Breast Tumor Growth In vivo

    Article • Clinical Cancer Research, July 2008, American Association for Cancer Research (AACR)

    Dr Penelope Dawn Ottewell

  31. Mechanisms of apoptosis and cell cycle arrest in sub-cutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid

    Article • European Journal of Cancer Supplements, July 2008, Elsevier

    Dr Penelope Dawn Ottewell

  32. Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid

    Article • May 2008, Springer Science + Business Media

    Dr Penelope Dawn Ottewell

  33. Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid

    Article • May 2008, Springer Science + Business Media

    Dr Penelope Dawn Ottewell

  34. P1. Breast cancer cells cause a reduction in osteoblast number – An early event in the development of osteolytic bone lesions

    Article • Cancer Treatment Reviews, January 2008, Elsevier

    Dr Penelope Dawn Ottewell

  35. P18. Mechanisms of apoptosis and cell cycle arrest in intra-tibial breast tumours treated sequentially with doxorubicin followed by zoledronic acid

    Article • Cancer Treatment Reviews, January 2008, Elsevier

    Dr Penelope Dawn Ottewell

  36. Zoledronic acid-induced IPP/ApppI production in vivo

    Article • Life Sciences, September 2007, Elsevier

    Dr Penelope Dawn Ottewell

  37. Gastrin Increases Murine Intestinal Crypt Regeneration Following Injury

    Article • Gastroenterology, April 2006, Elsevier

    Dr Penelope Dawn Ottewell

  38. Osteoprotegerin (OPG) expression in breast tumours and bone metastases

    Article • Bone, March 2006, Elsevier

    Dr Penelope Dawn Ottewell

  39. From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies

    Article • Breast Cancer Research and Treatment, December 2005, Springer Science + Business Media

    Dr Penelope Dawn Ottewell

  40. COOH-terminal 26-amino acid residues of progastrin are sufficient for stimulation of mitosis in murine colonic epithelium in vivo

    Article • AJP Gastrointestinal and Liver Physiology, October 2004, American Physiological Society

    Dr Penelope Dawn Ottewell

  41. Progastrin stimulates murine colonic epithelial mitosis after DNA damage

    Article • Gastroenterology, May 2003, Elsevier

    Dr Penelope Dawn Ottewell

  42. Elevated plasma concentrations of amidated gastrin cause increased crypt survival in murine intestinal epithelia after Γ-radiation

    Article • Gastroenterology, April 2003, Elsevier

    Dr Penelope Dawn Ottewell

  43. Progastrin stimulates murine colonic mitosis after DNA damage via the cyclin D1-cdk4 complex

    Article • Gastroenterology, April 2003, Elsevier

    Dr Penelope Dawn Ottewell

  44. Caspase activation during spontaneous and radiation‐induced apoptosis in the murine intestine

    Article • The Journal of Pathology, October 2001, Wiley

    Dr Penelope Dawn Ottewell

  45. Gene array and knockout mouse analysis of VP-16 induced apoptosis in the murine small intestine

    Article • Gastroenterology, April 2001, Elsevier

    Dr Penelope Dawn Ottewell

  46. Gene array and knockout mouse analysis of VP-16 induced apoptosis in the murine small intestine

    Article • Gastroenterology, April 2001, Elsevier

    Dr Penelope Dawn Ottewell

  47. Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine

    Article • The Journal of Pathology, January 2001, Wiley

    Dr Penelope Dawn Ottewell